Loading clinical trials...
Loading clinical trials...
A Phase III, 12-Week, Randomized, Active-Comparator-Controlled, Parallel-Group, Double Blind Study in Korea to Assess the Safety and Efficacy of Etoricoxib 30 mg Versus Celecoxib 200 mg in Patients With Osteoarthritis
Conditions
Interventions
Etoricoxib 30 mg
Celecoxib 200 mg
Start Date
March 1, 2012
Primary Completion Date
March 1, 2013
Completion Date
March 1, 2013
Last Updated
February 9, 2022
NCT06549686
NCT04992624
NCT07193368
NCT06927934
NCT06717529
NCT03005873
Lead Sponsor
Organon and Co
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions